FDA approves warfarin labeling change

Aug 16, 2007

The U.S. Food and Drug Administration has approved a labeling change for the widely used blood-thinning drug Coumadin (warfarin).

The Bristol-Myers Squibb Co. of Princeton, N.J., the manufacturer of Coumadin -- as well as manufacturers of warfarin, the generic version of the drug -- will add information to labels explaining a person's genetic makeup might influence how they respond to the drug. Research has shown a person's response to warfarin depends on variants of the genes CYP2C9 and VKORC1.

The FDA said the labeling change highlights the opportunity for healthcare providers to use genetic tests to improve their initial estimate of what is a reasonable warfarin dose for individual patients.

It's estimated about 2 million people start taking warfarin in the United States every year to prevent blood clots, heart attacks and stroke. Warfarin is a difficult drug to use because people taking a dose larger than they can tolerate are at risk of life-threatening bleeding. Those who receive too low a dose are at risk of equally dangerous blood clots.

Warfarin is the second most common drug -- after insulin --implicated in U.S. emergency room visits for adverse drug events.

Copyright 2007 by United Press International

Explore further: FDA approves hard-to-abuse narcotic painkiller

add to favorites email to friend print save as pdf

Related Stories

Model predicts a drug's likelihood of causing birth defects

Jan 04, 2011

When pregnant women need medications, there is often concern about possible effects on the fetus. Although some drugs are clearly recognized to cause birth defects (thalidomide being a notorious example), and others are generally ...

Success stops drug trial

Aug 31, 2010

The data monitoring committee of the AVERROES study, seeing overwhelming evidence of the success of apixaban in the prevention of stroke in patients with atrial fibrillation who are unsuitable for the conventional treatment ...

Study: Gene testing helps get warfarin dose right

Mar 16, 2010

(AP) -- Doctors are reporting an exciting win for gene testing and personalized medicine: Checking patients' DNA before starting them on a popular blood thinner helps get the tricky dose right and keep them out of the hospital.

FDA toughens warnings on over-the-counter painkillers

Apr 29, 2009

The Food and Drug Administration said Tuesday that it is asking drugmakers to more prominently display safety warnings on the labels of some of the most widely used over-the-counter pain and fever remedies.

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

Jul 24, 2014

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

Physicians warned about counterfeit medical devices

Jul 24, 2014

(HealthDay)—Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in ...

User comments : 0